TRVI Stock Recent News

Yesterday Trevi Therapeutics Inc's (NASDAQ: TRVI) Phase 2b/3 trial (PRISM) evaluating Haduvio (nalbuphine ER) for prurigo nodularis (PN) successfully met the key primary and secondary endpoints.  Needham writes that Haduvio had a quick onset of action, reaching stat sig at.

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment! The post Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data appeared first on InvestorPlace.

Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations.  In the trial, results.

NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention.

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Serge Belanger – Needham & Company Annabel Samimy – Stifel Nathan Weinstein – Aegis Capital Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Does Trevi Therapeutics, Inc. (TRVI) have what it takes to be a top stock pick for momentum investors? Let's find out.